Topics

eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy

2019-07-10 20:51:37 | BioPortfolio

Summary

Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.

Description

This Phase 2, open-label study will evaluate the safety, tolerability, antitumor activity, and pharmacokinetics (PK) of eFT508 in subjects who have initiated anti-PD-1/anti-PD-L1 monotherapy and either developed progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 on therapy or have undergone 12 weeks of anti-PD-1/anti-PD-L1 therapy with no evidence of partial response (PR) or complete response (CR).

Study Design

Conditions

Solid Tumors

Intervention

eFT508

Location

Universty of Toledo Medical Center
Toledo
Ohio
United States
43614

Status

Recruiting

Source

Effector Therapeutics

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-07-10T20:51:37-0400

Clinical Trials [2783 Associated Clinical Trials listed on BioPortfolio]

A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

This clinical trial is a Phase 1, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity...

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activi...

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer

This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerabil...

A Study Examining the Effect of eFT508 in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)

This Phase 2 study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of eFT508 in metastatic CRPC patients.

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastat...

PubMed Articles [5747 Associated PubMed Articles listed on BioPortfolio]

A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.

The prognosis for children with recurrent solid tumors generally is poor. Targeting mammalian target of rapamycin (mTOR) and vascular endothelial growth factor A with everolimus and bevacizumab, respe...

Leptomeningeal metastasis from solid tumors.

Central nervous system (CNS) metastasis from systemic cancers can involve the brain parenchyma, leptomeninges (pia, subarachnoid space and arachnoid mater), and dura. Leptomeningeal metastases (LM), a...

Solid tumor size of 2 cm divides outcomes of patients with mixed ground glass opacity lung tumors.

The prognosis of patients with cT1N0 lung adenocarcinoma is better when tumors includes mixed ground glass opacity (GGO) compared with pure solid tumors. However, whether the prognosis of patients wit...

Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases.

Data on the incidence, etiology, and prognosis of non-ventilator-associated pneumonia in hospitalized patients with solid tumors are scarce. We aimed to study the characteristics of non-ventilator-ass...

NY-ESO-1 expression in solid tumors predicts prognosis: A systematic review and meta-analysis.

New York esophageal squamous cell carcinoma 1 (NY-ESO-1) is a member of the cancer testis antigen family. NY-ESO-1 has documented potential as an effective target for cancer immunotherapy. The prognos...

Medical and Biotech [MESH] Definitions

An alkylating agent of value against both hematologic malignancies and solid tumors.

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.

A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.

A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.

More From BioPortfolio on "eFT508 in Combination With PD-1/PD-L1 Inhibitor Therapy"

Quick Search

Searches Linking to this Trial